# Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

> **NCT02215096** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 37 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK2636771
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02215096
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2019-10-03
- **Final completion:** 2019-10-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215096, "Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02215096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*